Profound Medical (PROF) to Release Quarterly Earnings on Monday

Profound Medical (NASDAQ:PROF – Get Rating) will be releasing its earnings data after the market closes on Monday, May 9th. Analysts expect Profound Medical to post earnings of ($0.45) per share for the quarter.

Profound Medical (NASDAQ:PROF – Get Rating) last issued its quarterly earnings data on Thursday, March 3rd. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.14). Profound Medical had a negative net margin of 446.65% and a negative return on equity of 34.89%. The business had revenue of $1.00 million during the quarter, compared to the consensus estimate of $2.80 million. During the same quarter last year, the business earned ($0.38) EPS. On average, analysts expect Profound Medical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

PROF opened at $7.30 on Monday. Profound Medical has a fifty-two week low of $6.95 and a fifty-two week high of $20.72. The stock’s 50 day simple moving average is $8.83. The company has a market cap of $151.69 million, a price-to-earnings ratio of -4.87 and a beta of 0.99.

Several analysts recently weighed in on PROF shares. Cowen reduced their price objective on shares of Profound Medical from $28.00 to $14.00 and set an “outperform” rating on the stock in a research note on Monday, March 7th. Raymond James set a $22.00 price target on Profound Medical and gave the company an “outperform” rating in a research report on Monday, April 25th. Finally, Zacks Investment Research downgraded Profound Medical from a “hold” rating to a “sell” rating in a research report on Saturday, January 22nd.

An institutional investor recently bought a new position in Profound Medical stock. D. E. Shaw & Co. Inc. purchased a new stake in Profound Medical Corp. (NASDAQ:PROF – Get Rating) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 10,715 shares of the company’s stock, valued at approximately $121,000. D. E. Shaw & Co. Inc. owned 0.05% of Profound Medical as of its most recent filing with the Securities & Exchange Commission. 46.63% of the stock is currently owned by institutional investors.

Profound Medical Company Profile (Get Rating)

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland.

Recommended Stories